Literature DB >> 22712058

Second trimester anti-angiogenic proteins and preeclampsia.

Catherine L Haggerty1, Michael E Seifert, Gong Tang, Jorn Olsen, Debra C Bass, S Ananth Karumanchi, Roberta B Ness.   

Abstract

OBJECTIVE: To measure the relationships between soluble fms-like tyrosine kinase-1 (sFlt1), soluble endoglin (sEng) and preeclampsia. STUDY
DESIGN: We utilized a nested case-control study comprised of 211 preeclamptic women and 213 normotensive women with primiparous singleton pregnancies enrolled from ≥13 and <27 gestational weeks among the Danish National Birth Cohort of 100,000 women. Relationships between sFlt1, sEng and preeclampsia were estimated using smoothing splines in generalized linear models, adjusting for maternal age, body mass index, pre-existing hypertension, smoking, and gestational age. MAIN OUTCOME MEASURES: Preeclampsia was confirmed by an International Classification of Diseases (ICD) discharge diagnosis of 637.03, 637.04 637.09, 637.19 (ICD-8) or DO14 to DO15 (ICD-10) in the National Hospital Discharge Registry. In this sample, few cases delivered small for gestational age infants (8.1%) and the mean gestational age at delivery was term (38.2 ± 2.3 weeks).
RESULTS: Doublings in the expressions of sFlt1 and sEng were associated with 39% (95% CI = 3%, 86%) and 74% (95% CI = 1%, 198%) increased risks of preeclampsia respectively.
CONCLUSIONS: We conclude that second trimester high sFlt1 and sEng levels were possibly associated with an increased risk of preeclampsia after adjustment for maternal factors traditionally associated with the syndrome.

Entities:  

Year:  2012        PMID: 22712058      PMCID: PMC3375839          DOI: 10.1016/j.preghy.2012.01.005

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  32 in total

1.  Contemporary concepts of the pathogenesis and management of preeclampsia.

Authors:  Kristine Y Lain; James M Roberts
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

Review 2.  Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?

Authors:  Naveed Sattar; Ian A Greer
Journal:  BMJ       Date:  2002-07-20

3.  Association between allelic variants in cytokine genes and preeclampsia.

Authors:  Catherine L Haggerty; Robert E Ferrell; Carl A Hubel; Nina Markovic; Gail Harger; Roberta B Ness
Journal:  Am J Obstet Gynecol       Date:  2005-07       Impact factor: 8.661

Review 4.  Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications.

Authors:  R B Ness; J M Roberts
Journal:  Am J Obstet Gynecol       Date:  1996-11       Impact factor: 8.661

5.  Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies.

Authors:  S Helske; P Vuorela; O Carpén; C Hornig; H Weich; E Halmesmäki
Journal:  Mol Hum Reprod       Date:  2001-02       Impact factor: 4.025

6.  Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia?

Authors:  A E Barden; L J Beilin; J Ritchie; B N Walters; C Michael
Journal:  J Hypertens       Date:  1999-09       Impact factor: 4.844

7.  Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia.

Authors:  S C Tidwell; H N Ho; W H Chiu; R J Torry; D S Torry
Journal:  Am J Obstet Gynecol       Date:  2001-05       Impact factor: 8.661

8.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Physiologic and supraphysiologic increases in lipoprotein lipids and apoproteins in late pregnancy and postpartum. Possible markers for the diagnosis of "prelipemia".

Authors:  A Montes; C E Walden; R H Knopp; M Cheung; M B Chapman; J J Albers
Journal:  Arteriosclerosis       Date:  1984 Jul-Aug

10.  Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.

Authors:  Sarosh Rana; S Ananth Karumanchi; Richard J Levine; Shivalingappa Venkatesha; Jose Alejandro Rauh-Hain; Hector Tamez; Ravi Thadhani
Journal:  Hypertension       Date:  2007-05-21       Impact factor: 10.190

View more
  4 in total

Review 1.  Angiogenic factors in preeclampsia: potential for diagnosis and treatment.

Authors:  Arvind Goel; Sarosh Rana
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

Review 2.  Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis.

Authors:  Yousef Veisani; Ensiyeh Jenabi; Ali Delpisheh; Salman Khazaei
Journal:  Int J Reprod Biomed       Date:  2019-03-03

3.  Preeclampsia is a biomarker for vascular disease in both mother and child: the need for a medical alert system.

Authors:  Julie Hakim; Mary K Senterman; Antoine M Hakim
Journal:  Int J Pediatr       Date:  2013-04-16

Review 4.  The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia.

Authors:  Pooneh Nikuei; Kianoosh Malekzadeh; Minoo Rajaei; Azim Nejatizadeh; Nasrin Ghasemi
Journal:  Iran J Reprod Med       Date:  2015-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.